Rakovina Therapeutics Inc. announced that the Company has received notice of allowance from the Untied States Patent and Trademark Office for a patent entitled “Tricyclic Inhibitors of Poly(ADP-Ribose) Polymerase.” The granted patent claims cover the composition of matter and uses of drug candidates from Rakovina Therapeutics’ kt-2000 series, one of three novel series of DNA-damage response (DDR) inhibitors being researched by the Company as potential targeted cancer therapies under a collaborative research agreement with the University of British Columbia. Rakovina Therapeutics’ kt-2000 series drug candidates are oral, targeted small-molecule inhibitors of poly (ADP-ribose) polymerase (PARP). PARP inhibitors have become integral in the treatment of cancers harboring deficiencies in homologous DNA repair (HR) leading to improved clinical outcomes in subsets of ovarian, breast and prostate cancer. Established data demonstrate that lead candidates from Rakovina Therapeutics’ kt-2000 series exhibit potency comparable to FDA-approved PARP-inhibitors and potent anti-cancer activity in preclinical animal models. Rakovina Therapeutics’ kt-2000 series lead candidates are being optimized around potential differentiating factors and competitive advantages, including the ability to cross the blood brain barrier in order to treat tumors that have metastasized to or originate in the brain.